<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00883051</url>
  </required_header>
  <id_info>
    <org_study_id>16892</org_study_id>
    <secondary_id>H8H-CD-LAHO</secondary_id>
    <secondary_id>2008-005010-43</secondary_id>
    <secondary_id>COL MIG-202</secondary_id>
    <nct_id>NCT00883051</nct_id>
  </id_info>
  <brief_title>Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment</brief_title>
  <official_title>A Double Blind Randomized Placebo-Controlled Parallel Group Dose-Ranging Study of Oral COL-144 in the Acute Treatment of Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CoLucid Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of a range of oral doses of
      COL-144 in treating migraine headache, in order to select a dose or doses for further
      evaluation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Migraine is a common chronic neurological disorder characterized by recurrent disabling
      episodes of moderate to severe headache accompanied by nausea, vomiting, photophobia, and
      phonophobia. Acute pharmacologic therapy for migraine aims to terminate the attack or reduce
      its severity. Analgesics are commonly used or, if these are ineffective, triptans. Since
      triptans are contraindicated in patients with coronary artery disease, uncontrolled
      hypertension, and cerebrovascular disease alternative medications are required for patients
      where simple analgesics do not work. COL-144 has no vasoconstrictor activity at clinically
      relevant concentrations and might meet this need. COL-144 was effective when given
      intravenously in a placebo-controlled dose-ranging study. This study investigates which dose
      of oral COL-144 is effective in the in acute treatment of migraine headache.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Headache Response</measure>
    <time_frame>2 hours postdose</time_frame>
    <description>Headache response is a binary response variable derived from the headache intensities recorded in the participant diary. Headache response is defined as a reduction in headache severity from moderate or severe at baseline to mild or no headache, at two hours after administration of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Are Headache Free (Absence of Headache) After First Dose</measure>
    <time_frame>2 hours post dose</time_frame>
    <description>The percentage of participants defined as mild, moderate, or severe headache pain becoming none.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Headache Recurrence</measure>
    <time_frame>up to 24 hours postdose</time_frame>
    <description>Participants who received study drug and which became pain free at 2 hours postdose and worsened again upto 24 hours post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Headache Severity (4 Point Rating Scale)</measure>
    <time_frame>2 hours postdose</time_frame>
    <description>Headache severity was evaluated by the participant using the International Headache Society (IHS) four point headache severity rating scale (0=no pain, 1=mild pain, 2=moderate pain, and 3=severe pain) with a lower score being less severe and a higher score being more severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Have Symptoms of Nausea</measure>
    <time_frame>2 hours postdose</time_frame>
    <description>Percentage of participants who have symptoms of nausea two hours post treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Have Symptoms Phonophobia</measure>
    <time_frame>2 hours postdose</time_frame>
    <description>Percentage of participants who have symptoms of phonophobia two hours post treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Have Photophobia</measure>
    <time_frame>2 hours postdose</time_frame>
    <description>Percentage of participants who have symptoms of photophobia two hours post treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Vomiting</measure>
    <time_frame>2 hours postdose</time_frame>
    <description>Percentage of participants with vomiting 2 hours post treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability (4 Point Scale: Not at All, Mild Interference, Marked Interference, Completely - Needs Bed Rest)</measure>
    <time_frame>2 hours postdose</time_frame>
    <description>The participant is asked &quot;How much is the migraine interfering with normal activities?&quot; on a 4 point scale 0-Not at all, 1-Mild interference, 2-Marked interference ,3-Completely needs bed rest, with a lower score having lower interference and higher score worse interference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Used Rescue Medication</measure>
    <time_frame>Postdose 2 through 24 hours</time_frame>
    <description>Rescue medication was permitted after completion of the 2 hour assessment if migraine did not respond (participant was not pain free).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting a Score on the Patient Global Impression of Improvement (PGI-I)</measure>
    <time_frame>2 hours postdose</time_frame>
    <description>PGI-I requests participants to mark the box that best describes their cluster headache condition since they started taking the medicine. The options in the displayed boxes are represented on a 7-point scale, with 1 = very much better, 2 = much better, 3 = a little better, 4 = no change, 5 = a little worse, 6 = much worse, and 7 = very much worse, a lower number indicates much better and a higher number indicates worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Actual Time to Headache Relief and Time to Pain Free</measure>
    <time_frame>up to 24 hours postdose</time_frame>
    <description>The participant answered &quot;Did your migraine pain go away completely (pain free) within 24 hours of dosing&quot; and record the time.
Actual time to meaningful pain relief and actual time to pain free will be censored at 24 hours if meaningful pain relief or pain free is documented to be greater than 24 hours after dosing and &quot;Did you experience meaningful relief (headache relief) from your migraine within 24 hours after dosing?&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Heart Rate</measure>
    <time_frame>Baseline through Day 14</time_frame>
    <description>Change from baseline in assessment of vital signs (heart rate).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure</measure>
    <time_frame>Baseline through Day 14</time_frame>
    <description>Change from baseline in vital signs (systolic blood pressure).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Diastolic Blood Pressure</measure>
    <time_frame>Baseline through Day 14</time_frame>
    <description>Change from baseline in vital signs (diastolic blood pressure).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Change From Baseline in Physical Examination Parameters</measure>
    <time_frame>Baseline through Day 14</time_frame>
    <description>Participants were evaluated for skin, head, ear, nose and throat, cardiovascular and musculoskeletal changes from a normal screening to an abnormal screening. Changes in the physical examination noted as non-serious AEs or SAEs, regardless of causality, are located in the Reported Adverse Events section.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hematology Tests</measure>
    <time_frame>Baseline through Day 14</time_frame>
    <description>Hematology tests, including a complete blood count (CBC) measured red blood cells, white blood cells, hemoglobin, neutrophils and platelets.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Serious Adverse Events</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>A summary of non-serious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">512</enrollment>
  <condition>Migraine Disorders</condition>
  <arm_group>
    <arm_group_label>50 mg Lasmiditan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg lasmiditan administered orally (PO)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg Lasmiditan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg lasmiditan administered orally (PO)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg Lasmiditan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg lasmiditan administered orally (PO)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>400 mg Lasmiditan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg lasmiditan administered orally (PO)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally (PO)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasmiditan</intervention_name>
    <description>Oral application of one dose of either 50 mg lasmiditan,100 mg lasmiditan, 200 mg lasmiditan, 400 mg lasmiditan or placebo as the first treatment for a new migraine attack providing that any aura symptoms have resolved and the headache is either moderate or severe and has been so for less than 4 hours.</description>
    <arm_group_label>100 mg Lasmiditan</arm_group_label>
    <arm_group_label>200 mg Lasmiditan</arm_group_label>
    <arm_group_label>400 mg Lasmiditan</arm_group_label>
    <arm_group_label>50 mg Lasmiditan</arm_group_label>
    <other_name>LY573144</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with migraine with or without aura fulfilling the IHS diagnostic criteria 1.1
             and 1.2.1 (2004)

          -  History of migraine of at least 1 year

          -  Migraine onset before the age of 50 years

          -  History of 1 - 8 migraine attacks per month

          -  Male or female patients aged 18 to 65 years

          -  Female patients of child-bearing potential must be using a highly effective form of
             contraception (e.g., combined oral contraceptive, IUD, abstinence, vasectomized
             partner)

          -  Able and willing to give written informed consent

          -  Able and willing to complete a migraine diary card to record details of the attack
             treated with study medication

        Exclusion Criteria:

          -  History of life threatening or intolerable adverse reaction to any triptan

          -  Use of prescription migraine prophylactic drugs within 15 days (30 days for
             flunarizine) prior to Screening Visit and during study participation

          -  Using herbal preparations (e.g., feverfew, butterbur) for migraine prophylaxis

          -  Using 5-HT reuptake inhibitors

          -  Using drugs known to inhibit CYP450 enzymes (see Appendix 2 for details)

          -  Pregnant or breast-feeding women

          -  Women of child-bearing potential not using highly effective contraception

          -  History or evidence of coronary artery disease, ischemic or hemorrhagic stroke,
             epilepsy or any other condition placing the patient at increased risk of seizures

          -  History of hypertension (controlled or uncontrolled)

          -  History of orthostatic hypotension

          -  Current use of hemodynamically active cardiovascular drugs

          -  History within the previous 3 years or current evidence of abuse of any drug,
             prescription or illicit, or alcohol

          -  Significant renal or hepatic impairment

          -  Previous participation in this clinical trial

          -  Participation in any clinical trial of an experimental drug or device in the previous
             30 days

          -  Any medical condition or laboratory test which in the judgment of the investigator
             makes the patient unsuitable for the study

          -  Known Hepatitis B or C or HIV infection

          -  Patients who are employees of the sponsor

          -  Relatives of, or staff directly reporting to, the investigator

          -  Patients with known hypersensitivity to COL-144, other 5HT1F receptor agonists or to
             any excipient of COL-144 drug product

          -  Patients who were treated with study medication in the COL MIG-201 study (Patients
             screened but not treated under that protocol are not excluded)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Montegnee</city>
        <state>Liege</state>
        <zip>4420</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hasselt</city>
        <state>Limburg</state>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brugge</city>
        <state>West-Vlaanderen</state>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Helsinki</city>
        <state>Etelä-Suomi</state>
        <zip>00029 HUS</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hyvinkää</city>
        <state>Etelä-Suomi</state>
        <zip>05850</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mikkeli</city>
        <state>Itä-Suomen Lääni</state>
        <zip>50100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pori</city>
        <state>Länsi-Suomen</state>
        <zip>28100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jyväskylä</city>
        <state>Länsi-Suomi</state>
        <zip>40100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampere</city>
        <state>Länsi-Suomi</state>
        <zip>33200</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Turku</city>
        <state>Länsi-Suomi</state>
        <zip>20100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nice</city>
        <state>Alpes-Maritimes</state>
        <zip>06002</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bordeaux</city>
        <state>Gironde</state>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse</city>
        <state>Haute-Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59 037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rouen</city>
        <state>Seine-Maritime</state>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Freiburg/Breisgau</city>
        <state>Baden-Württemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Göppingen</city>
        <state>Baden-Württemberg</state>
        <zip>73033</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>80802</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wiesbaden</city>
        <state>Hessen</state>
        <zip>65189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erkelenz</city>
        <state>Nordrhein-Westfalen</state>
        <zip>41812</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Münster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Itzehoe</city>
        <state>Schleswig-Holstein</state>
        <zip>25524</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bremen</city>
        <zip>28329</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <state>Andalucía</state>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gandia</city>
        <state>Comunidad Valenciana</state>
        <zip>46701</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46021</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago de Compostela</city>
        <state>Comunidade Autónoma De Galicia</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alcorcon</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pamplona</city>
        <state>Nafarroako Foru Komunitatea</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oviedo</city>
        <state>Principado De Asturias</state>
        <zip>33007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>April 16, 2009</study_first_submitted>
  <study_first_submitted_qc>April 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2009</study_first_posted>
  <results_first_submitted>November 8, 2019</results_first_submitted>
  <results_first_submitted_qc>December 20, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 23, 2019</results_first_posted>
  <last_update_submitted>December 20, 2019</last_update_submitted>
  <last_update_submitted_qc>December 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COL-144</keyword>
  <keyword>acute treatment</keyword>
  <keyword>migraine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>50 mg Lasmiditan</title>
          <description>50 mg lasmiditan administered PO within 4 hours of a migraine attack</description>
        </group>
        <group group_id="P2">
          <title>100 mg Lasmiditan</title>
          <description>100 mg lasmiditan administered PO within 4 hours of a migraine attack</description>
        </group>
        <group group_id="P3">
          <title>200 mg Lasmiditan</title>
          <description>200 mg lasmiditan administered PO within 4 hours of a migraine attack</description>
        </group>
        <group group_id="P4">
          <title>400 mg Lasmiditan</title>
          <description>400 mg lasmiditan administered PO within 4 hours of a migraine attack</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Placebo administered PO within 4 hours of a migraine attack</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="104"/>
                <participants group_id="P3" count="100"/>
                <participants group_id="P4" count="99"/>
                <participants group_id="P5" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>No Study Medication Used</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="29"/>
                <participants group_id="P5" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="82"/>
                <participants group_id="P3" count="71"/>
                <participants group_id="P4" count="70"/>
                <participants group_id="P5" count="86"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="82"/>
                <participants group_id="P3" count="71"/>
                <participants group_id="P4" count="70"/>
                <participants group_id="P5" count="85">One participant was lost to follow up and did not provide adverse event data.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="29"/>
                <participants group_id="P5" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not use study medication</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="29"/>
                <participants group_id="P5" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants who received at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>50 mg Lasmiditan</title>
          <description>50 mg lasmiditan administered PO within 4 hours of a migraine attack</description>
        </group>
        <group group_id="B2">
          <title>100 mg Lasmiditan</title>
          <description>100 mg lasmiditan administered PO within 4 hours of a migraine attack</description>
        </group>
        <group group_id="B3">
          <title>200 mg Lasmiditan</title>
          <description>200 mg lasmiditan administered PO within 4 hours of a migraine attack</description>
        </group>
        <group group_id="B4">
          <title>400 mg Lasmiditan</title>
          <description>400 mg lasmiditan administered PO within 4 hours of a migraine attack</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Placebo administered PO within 4 hours of a migraine attack</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="82"/>
            <count group_id="B2" value="82"/>
            <count group_id="B3" value="71"/>
            <count group_id="B4" value="70"/>
            <count group_id="B5" value="86"/>
            <count group_id="B6" value="391"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41" lower_limit="18" upper_limit="65"/>
                    <measurement group_id="B2" value="45" lower_limit="20" upper_limit="65"/>
                    <measurement group_id="B3" value="41" lower_limit="18" upper_limit="57"/>
                    <measurement group_id="B4" value="40" lower_limit="20" upper_limit="60"/>
                    <measurement group_id="B5" value="41" lower_limit="19" upper_limit="66"/>
                    <measurement group_id="B6" value="41.0" lower_limit="18.0" upper_limit="66.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="65"/>
                    <measurement group_id="B5" value="75"/>
                    <measurement group_id="B6" value="342"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="69"/>
                    <measurement group_id="B5" value="86"/>
                    <measurement group_id="B6" value="390"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="69"/>
                    <measurement group_id="B5" value="86"/>
                    <measurement group_id="B6" value="387"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="30"/>
                    <measurement group_id="B6" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="32"/>
                    <measurement group_id="B6" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Headache Response</title>
        <description>Headache response is a binary response variable derived from the headache intensities recorded in the participant diary. Headache response is defined as a reduction in headache severity from moderate or severe at baseline to mild or no headache, at two hours after administration of study drug.</description>
        <time_frame>2 hours postdose</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had a post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Lasmiditan</title>
            <description>50 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O2">
            <title>100 mg Lasmiditan</title>
            <description>100 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O3">
            <title>200 mg Lasmiditan</title>
            <description>200 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O4">
            <title>400 mg Lasmiditan</title>
            <description>400 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally (PO)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Headache Response</title>
          <description>Headache response is a binary response variable derived from the headache intensities recorded in the participant diary. Headache response is defined as a reduction in headache severity from moderate or severe at baseline to mild or no headache, at two hours after administration of study drug.</description>
          <population>All randomized participants who received at least 1 dose of study drug and had a post-baseline evaluation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.0"/>
                    <measurement group_id="O2" value="35.8"/>
                    <measurement group_id="O3" value="49.3"/>
                    <measurement group_id="O4" value="35.3"/>
                    <measurement group_id="O5" value="74.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.0"/>
                    <measurement group_id="O2" value="64.2"/>
                    <measurement group_id="O3" value="50.7"/>
                    <measurement group_id="O4" value="64.7"/>
                    <measurement group_id="O5" value="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A hierarchical test procedure was applied only for analysis of the primary efficacy endpoint.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Armitage test for trend</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Are Headache Free (Absence of Headache) After First Dose</title>
        <description>The percentage of participants defined as mild, moderate, or severe headache pain becoming none.</description>
        <time_frame>2 hours post dose</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug, a 2 hour postdose evaluation and evaluable headache relief data.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Lasmiditan</title>
            <description>50 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O2">
            <title>100 mg Lasmiditan</title>
            <description>100 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O3">
            <title>200 mg Lasmiditan</title>
            <description>200 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O4">
            <title>400 mg Lasmiditan</title>
            <description>400 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally (PO)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Are Headache Free (Absence of Headache) After First Dose</title>
          <description>The percentage of participants defined as mild, moderate, or severe headache pain becoming none.</description>
          <population>All randomized participants who received at least 1 dose of study drug, a 2 hour postdose evaluation and evaluable headache relief data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9"/>
                    <measurement group_id="O2" value="13.6"/>
                    <measurement group_id="O3" value="18.8"/>
                    <measurement group_id="O4" value="27.9"/>
                    <measurement group_id="O5" value="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A hierarchical test procedure was applied only for analysis of the primary efficacy endpoint.</non_inferiority_desc>
            <p_value>=0.0006</p_value>
            <method>Cochran-Armitage test for trend]</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Headache Recurrence</title>
        <description>Participants who received study drug and which became pain free at 2 hours postdose and worsened again upto 24 hours post-dose.</description>
        <time_frame>up to 24 hours postdose</time_frame>
        <population>Randomized participants who received a dose of study drug, were pain free at 2 hours postdose and had postdose headache severity or symptom assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Lasmiditan</title>
            <description>50 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O2">
            <title>100 mg Lasmiditan</title>
            <description>100 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O3">
            <title>200 mg Lasmiditan</title>
            <description>200 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O4">
            <title>400 mg Lasmiditan</title>
            <description>400 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally (PO)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Headache Recurrence</title>
          <description>Participants who received study drug and which became pain free at 2 hours postdose and worsened again upto 24 hours post-dose.</description>
          <population>Randomized participants who received a dose of study drug, were pain free at 2 hours postdose and had postdose headache severity or symptom assessments.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="44"/>
                <count group_id="O5" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.9"/>
                    <measurement group_id="O2" value="57.7"/>
                    <measurement group_id="O3" value="62.9"/>
                    <measurement group_id="O4" value="50.0"/>
                    <measurement group_id="O5" value="57.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Headache Severity (4 Point Rating Scale)</title>
        <description>Headache severity was evaluated by the participant using the International Headache Society (IHS) four point headache severity rating scale (0=no pain, 1=mild pain, 2=moderate pain, and 3=severe pain) with a lower score being less severe and a higher score being more severe.</description>
        <time_frame>2 hours postdose</time_frame>
        <population>Randomized participants who received a dose of study drug and had postdose headache severity or symptom assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Lasmiditan</title>
            <description>50 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O2">
            <title>100 mg Lasmiditan</title>
            <description>100 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O3">
            <title>200 mg Lasmiditan</title>
            <description>200 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O4">
            <title>400 mg Lasmiditan</title>
            <description>400 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally (PO)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Headache Severity (4 Point Rating Scale)</title>
          <description>Headache severity was evaluated by the participant using the International Headache Society (IHS) four point headache severity rating scale (0=no pain, 1=mild pain, 2=moderate pain, and 3=severe pain) with a lower score being less severe and a higher score being more severe.</description>
          <population>Randomized participants who received a dose of study drug and had postdose headache severity or symptom assessments.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="67"/>
                <count group_id="O5" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9"/>
                    <measurement group_id="O2" value="13.6"/>
                    <measurement group_id="O3" value="18.8"/>
                    <measurement group_id="O4" value="27.9"/>
                    <measurement group_id="O5" value="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild(1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.1"/>
                    <measurement group_id="O2" value="50.6"/>
                    <measurement group_id="O3" value="31.9"/>
                    <measurement group_id="O4" value="36.8"/>
                    <measurement group_id="O5" value="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate(2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8"/>
                    <measurement group_id="O2" value="23.5"/>
                    <measurement group_id="O3" value="26.1"/>
                    <measurement group_id="O4" value="20.6"/>
                    <measurement group_id="O5" value="27.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe(3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.1"/>
                    <measurement group_id="O2" value="11.1"/>
                    <measurement group_id="O3" value="21.7"/>
                    <measurement group_id="O4" value="13.2"/>
                    <measurement group_id="O5" value="46.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Have Symptoms of Nausea</title>
        <description>Percentage of participants who have symptoms of nausea two hours post treatment.</description>
        <time_frame>2 hours postdose</time_frame>
        <population>Randomized participants who received a dose of study drug and had postdose symptom assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Lasmiditan</title>
            <description>50 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O2">
            <title>100 mg Lasmiditan</title>
            <description>100 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O3">
            <title>200 mg Lasmiditan</title>
            <description>200 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O4">
            <title>400 mg Lasmiditan</title>
            <description>400 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally (PO)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Have Symptoms of Nausea</title>
          <description>Percentage of participants who have symptoms of nausea two hours post treatment.</description>
          <population>Randomized participants who received a dose of study drug and had postdose symptom assessments.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="67"/>
                <count group_id="O5" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.65"/>
                    <measurement group_id="O2" value="25.00"/>
                    <measurement group_id="O3" value="35.29"/>
                    <measurement group_id="O4" value="26.87"/>
                    <measurement group_id="O5" value="40.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Have Symptoms Phonophobia</title>
        <description>Percentage of participants who have symptoms of phonophobia two hours post treatment.</description>
        <time_frame>2 hours postdose</time_frame>
        <population>Randomized participants who received a dose of study drug and had postdose symptom assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Lasmiditan</title>
            <description>50 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O2">
            <title>100 mg Lasmiditan</title>
            <description>100 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O3">
            <title>200 mg Lasmiditan</title>
            <description>200 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O4">
            <title>400 mg Lasmiditan</title>
            <description>400 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally (PO)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Have Symptoms Phonophobia</title>
          <description>Percentage of participants who have symptoms of phonophobia two hours post treatment.</description>
          <population>Randomized participants who received a dose of study drug and had postdose symptom assessments.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="67"/>
                <count group_id="O5" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.77"/>
                    <measurement group_id="O2" value="23.75"/>
                    <measurement group_id="O3" value="39.71"/>
                    <measurement group_id="O4" value="31.34"/>
                    <measurement group_id="O5" value="48.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Have Photophobia</title>
        <description>Percentage of participants who have symptoms of photophobia two hours post treatment.</description>
        <time_frame>2 hours postdose</time_frame>
        <population>Randomized participants who received a dose of study drug and had postdose symptom assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Lasmiditan</title>
            <description>50 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O2">
            <title>100 mg Lasmiditan</title>
            <description>100 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O3">
            <title>200 mg Lasmiditan</title>
            <description>200 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O4">
            <title>400 mg Lasmiditan</title>
            <description>400 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally (PO)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Have Photophobia</title>
          <description>Percentage of participants who have symptoms of photophobia two hours post treatment.</description>
          <population>Randomized participants who received a dose of study drug and had postdose symptom assessments.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="67"/>
                <count group_id="O5" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.84"/>
                    <measurement group_id="O2" value="31.25"/>
                    <measurement group_id="O3" value="41.18"/>
                    <measurement group_id="O4" value="37.31"/>
                    <measurement group_id="O5" value="65.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Vomiting</title>
        <description>Percentage of participants with vomiting 2 hours post treatment.</description>
        <time_frame>2 hours postdose</time_frame>
        <population>Randomized participants who received a dose of study drug and had postdose symptom assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Lasmiditan</title>
            <description>50 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O2">
            <title>100 mg Lasmiditan</title>
            <description>100 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O3">
            <title>200 mg Lasmiditan</title>
            <description>200 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O4">
            <title>400 mg Lasmiditan</title>
            <description>400 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally (PO)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Vomiting</title>
          <description>Percentage of participants with vomiting 2 hours post treatment.</description>
          <population>Randomized participants who received a dose of study drug and had postdose symptom assessments.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="67"/>
                <count group_id="O5" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.06"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="7.35"/>
                    <measurement group_id="O4" value="4.80"/>
                    <measurement group_id="O5" value="11.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disability (4 Point Scale: Not at All, Mild Interference, Marked Interference, Completely - Needs Bed Rest)</title>
        <description>The participant is asked &quot;How much is the migraine interfering with normal activities?&quot; on a 4 point scale 0-Not at all, 1-Mild interference, 2-Marked interference ,3-Completely needs bed rest, with a lower score having lower interference and higher score worse interference.</description>
        <time_frame>2 hours postdose</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Lasmiditan</title>
            <description>50 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O2">
            <title>100 mg Lasmiditan</title>
            <description>100 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O3">
            <title>200 mg Lasmiditan</title>
            <description>200 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O4">
            <title>400 mg Lasmiditan</title>
            <description>400 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally (PO)</description>
          </group>
        </group_list>
        <measure>
          <title>Disability (4 Point Scale: Not at All, Mild Interference, Marked Interference, Completely - Needs Bed Rest)</title>
          <description>The participant is asked &quot;How much is the migraine interfering with normal activities?&quot; on a 4 point scale 0-Not at all, 1-Mild interference, 2-Marked interference ,3-Completely needs bed rest, with a lower score having lower interference and higher score worse interference.</description>
          <population>All randomized participants who received at least 1 dose of study drug and had evaluable data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="63"/>
                <count group_id="O5" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild interference (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Marked interference (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Completely needs bed rest (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Used Rescue Medication</title>
        <description>Rescue medication was permitted after completion of the 2 hour assessment if migraine did not respond (participant was not pain free).</description>
        <time_frame>Postdose 2 through 24 hours</time_frame>
        <population>Randomized participants who received a dose of study drug and had postdose headache severity or symptom assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Lasmiditan</title>
            <description>50 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O2">
            <title>100 mg Lasmiditan</title>
            <description>100 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O3">
            <title>200 mg Lasmiditan</title>
            <description>200 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O4">
            <title>400 mg Lasmiditan</title>
            <description>400 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally (PO)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Used Rescue Medication</title>
          <description>Rescue medication was permitted after completion of the 2 hour assessment if migraine did not respond (participant was not pain free).</description>
          <population>Randomized participants who received a dose of study drug and had postdose headache severity or symptom assessments.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.5"/>
                    <measurement group_id="O2" value="51.9"/>
                    <measurement group_id="O3" value="61.2"/>
                    <measurement group_id="O4" value="41.8"/>
                    <measurement group_id="O5" value="68.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting a Score on the Patient Global Impression of Improvement (PGI-I)</title>
        <description>PGI-I requests participants to mark the box that best describes their cluster headache condition since they started taking the medicine. The options in the displayed boxes are represented on a 7-point scale, with 1 = very much better, 2 = much better, 3 = a little better, 4 = no change, 5 = a little worse, 6 = much worse, and 7 = very much worse, a lower number indicates much better and a higher number indicates worse.</description>
        <time_frame>2 hours postdose</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had a PGI-I measurement post dose.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Lasmiditan</title>
            <description>50 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O2">
            <title>100 mg Lasmiditan</title>
            <description>100 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O3">
            <title>200 mg Lasmiditan</title>
            <description>200 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O4">
            <title>400 mg Lasmiditan</title>
            <description>400 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally (PO)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting a Score on the Patient Global Impression of Improvement (PGI-I)</title>
          <description>PGI-I requests participants to mark the box that best describes their cluster headache condition since they started taking the medicine. The options in the displayed boxes are represented on a 7-point scale, with 1 = very much better, 2 = much better, 3 = a little better, 4 = no change, 5 = a little worse, 6 = much worse, and 7 = very much worse, a lower number indicates much better and a higher number indicates worse.</description>
          <population>All randomized participants who received at least 1 dose of study drug and had a PGI-I measurement post dose.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="67"/>
                <count group_id="O5" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very much better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A little better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A little worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Actual Time to Headache Relief and Time to Pain Free</title>
        <description>The participant answered &quot;Did your migraine pain go away completely (pain free) within 24 hours of dosing&quot; and record the time.
Actual time to meaningful pain relief and actual time to pain free will be censored at 24 hours if meaningful pain relief or pain free is documented to be greater than 24 hours after dosing and &quot;Did you experience meaningful relief (headache relief) from your migraine within 24 hours after dosing?&quot;.</description>
        <time_frame>up to 24 hours postdose</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Lasmiditan</title>
            <description>50 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O2">
            <title>100 mg Lasmiditan</title>
            <description>100 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O3">
            <title>200 mg Lasmiditan</title>
            <description>200 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O4">
            <title>400 mg Lasmiditan</title>
            <description>400 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally (PO)</description>
          </group>
        </group_list>
        <measure>
          <title>Actual Time to Headache Relief and Time to Pain Free</title>
          <description>The participant answered &quot;Did your migraine pain go away completely (pain free) within 24 hours of dosing&quot; and record the time.
Actual time to meaningful pain relief and actual time to pain free will be censored at 24 hours if meaningful pain relief or pain free is documented to be greater than 24 hours after dosing and &quot;Did you experience meaningful relief (headache relief) from your migraine within 24 hours after dosing?&quot;.</description>
          <population>All randomized participants who received at least 1 dose of study drug.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="650.87" spread="77.53"/>
                    <measurement group_id="O2" value="291.05" spread="32.24"/>
                    <measurement group_id="O3" value="407.16" spread="52.48"/>
                    <measurement group_id="O4" value="218.93" spread="23.87"/>
                    <measurement group_id="O5" value="760.15" spread="71.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain free</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="871.27" spread="72.74"/>
                    <measurement group_id="O2" value="767.33" spread="74.36"/>
                    <measurement group_id="O3" value="690.89" spread="59.67"/>
                    <measurement group_id="O4" value="437.12" spread="36.05"/>
                    <measurement group_id="O5" value="1046.47" spread="77.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Heart Rate</title>
        <description>Change from baseline in assessment of vital signs (heart rate).</description>
        <time_frame>Baseline through Day 14</time_frame>
        <population>Randomized participants who received at least 1 dose of study drug and had evaluable ECG parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Lasmiditan</title>
            <description>50 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O2">
            <title>100 mg Lasmiditan</title>
            <description>100 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O3">
            <title>200 mg Lasmiditan</title>
            <description>200 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O4">
            <title>400 mg Lasmiditan</title>
            <description>400 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally (PO)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Heart Rate</title>
          <description>Change from baseline in assessment of vital signs (heart rate).</description>
          <population>Randomized participants who received at least 1 dose of study drug and had evaluable ECG parameters.</population>
          <units>beats per minute</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="-27.0" upper_limit="28.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="-16.0" upper_limit="24.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="-18.0" upper_limit="28.0"/>
                    <measurement group_id="O4" value="2.0" lower_limit="-21.0" upper_limit="28.0"/>
                    <measurement group_id="O5" value="1.0" lower_limit="-66.0" upper_limit="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Systolic Blood Pressure</title>
        <description>Change from baseline in vital signs (systolic blood pressure).</description>
        <time_frame>Baseline through Day 14</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had evaluable blood pressure.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Lasmiditan</title>
            <description>50 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O2">
            <title>100 mg Lasmiditan</title>
            <description>100 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O3">
            <title>200 mg Lasmiditan</title>
            <description>200 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O4">
            <title>400 mg Lasmiditan</title>
            <description>400 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally (PO)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure</title>
          <description>Change from baseline in vital signs (systolic blood pressure).</description>
          <population>All randomized participants who received at least 1 dose of study drug and had evaluable blood pressure.</population>
          <units>millimeters of mercury</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="-30.0" upper_limit="29.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-25.0" upper_limit="42.0"/>
                    <measurement group_id="O3" value="-1.5" lower_limit="-23.0" upper_limit="35.0"/>
                    <measurement group_id="O4" value="-0.5" lower_limit="-35.0" upper_limit="36.0"/>
                    <measurement group_id="O5" value="-0.0" lower_limit="-30.0" upper_limit="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Diastolic Blood Pressure</title>
        <description>Change from baseline in vital signs (diastolic blood pressure).</description>
        <time_frame>Baseline through Day 14</time_frame>
        <population>Randomized participants who received at least 1 dose of study drug and had evaluable blood pressure.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Lasmiditan</title>
            <description>50 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O2">
            <title>100 mg Lasmiditan</title>
            <description>100 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O3">
            <title>200 mg Lasmiditan</title>
            <description>200 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O4">
            <title>400 mg Lasmiditan</title>
            <description>400 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally (PO)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Diastolic Blood Pressure</title>
          <description>Change from baseline in vital signs (diastolic blood pressure).</description>
          <population>Randomized participants who received at least 1 dose of study drug and had evaluable blood pressure.</population>
          <units>millimeters of mercury</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-14.0" upper_limit="21.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-20.0" upper_limit="25.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-22.0" upper_limit="15.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-20.0" upper_limit="20.0"/>
                    <measurement group_id="O5" value="0.0" lower_limit="-20.0" upper_limit="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Change From Baseline in Physical Examination Parameters</title>
        <description>Participants were evaluated for skin, head, ear, nose and throat, cardiovascular and musculoskeletal changes from a normal screening to an abnormal screening. Changes in the physical examination noted as non-serious AEs or SAEs, regardless of causality, are located in the Reported Adverse Events section.</description>
        <time_frame>Baseline through Day 14</time_frame>
        <population>All randomized participants who received at last 1 dose of study drug and had a physical examination.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Lasmiditan</title>
            <description>50 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O2">
            <title>100 mg Lasmiditan</title>
            <description>100 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O3">
            <title>200 mg Lasmiditan</title>
            <description>200 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O4">
            <title>400 mg Lasmiditan</title>
            <description>400 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally (PO)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Change From Baseline in Physical Examination Parameters</title>
          <description>Participants were evaluated for skin, head, ear, nose and throat, cardiovascular and musculoskeletal changes from a normal screening to an abnormal screening. Changes in the physical examination noted as non-serious AEs or SAEs, regardless of causality, are located in the Reported Adverse Events section.</description>
          <population>All randomized participants who received at last 1 dose of study drug and had a physical examination.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Skin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="2.4"/>
                    <measurement group_id="O3" value="1.4"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head, ears, nose, throat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1.4"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Musculoskeletal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1.2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hematology Tests</title>
        <description>Hematology tests, including a complete blood count (CBC) measured red blood cells, white blood cells, hemoglobin, neutrophils and platelets.</description>
        <time_frame>Baseline through Day 14</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had evaluable blood parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Lasmiditan</title>
            <description>50 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O2">
            <title>100 mg Lasmiditan</title>
            <description>100 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O3">
            <title>200 mg Lasmiditan</title>
            <description>200 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O4">
            <title>400 mg Lasmiditan</title>
            <description>400 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally (PO)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Tests</title>
          <description>Hematology tests, including a complete blood count (CBC) measured red blood cells, white blood cells, hemoglobin, neutrophils and platelets.</description>
          <population>All randomized participants who received at least 1 dose of study drug and had evaluable blood parameters.</population>
          <units>million cells per liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemoglobin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.4"/>
                    <measurement group_id="O2" value="0.0" spread="0.4"/>
                    <measurement group_id="O3" value="0.1" spread="0.4"/>
                    <measurement group_id="O4" value="0.0" spread="0.4"/>
                    <measurement group_id="O5" value="0.0" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.2"/>
                    <measurement group_id="O2" value="0.0" spread="0.2"/>
                    <measurement group_id="O3" value="0.0" spread="0.2"/>
                    <measurement group_id="O4" value="0.0" spread="0.2"/>
                    <measurement group_id="O5" value="0.0" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White blood cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="1.3"/>
                    <measurement group_id="O2" value="0.3" spread="1.4"/>
                    <measurement group_id="O3" value="-0.3" spread="1.6"/>
                    <measurement group_id="O4" value="-0.4" spread="1.7"/>
                    <measurement group_id="O5" value="-0.2" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="9.3"/>
                    <measurement group_id="O2" value="-0.3" spread="7.9"/>
                    <measurement group_id="O3" value="-2.8" spread="14.7"/>
                    <measurement group_id="O4" value="-3.2" spread="14.7"/>
                    <measurement group_id="O5" value="-3.9" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="35.2"/>
                    <measurement group_id="O2" value="-0.5" spread="25.9"/>
                    <measurement group_id="O3" value="4.6" spread="48.4"/>
                    <measurement group_id="O4" value="2.9" spread="34.7"/>
                    <measurement group_id="O5" value="1.7" spread="34.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Serious Adverse Events</title>
        <description>A summary of non-serious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.</description>
        <time_frame>up to 8 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug excluding one participant who was lost to follow-up and did not report adverse events.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Lasmiditan</title>
            <description>50 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O2">
            <title>100 mg Lasmiditan</title>
            <description>100 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O3">
            <title>200 mg Lasmiditan</title>
            <description>200 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O4">
            <title>400 mg Lasmiditan</title>
            <description>400 mg lasmiditan administered orally (PO)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally (PO)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Serious Adverse Events</title>
          <description>A summary of non-serious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.</description>
          <population>All randomized participants who received at least 1 dose of study drug excluding one participant who was lost to follow-up and did not report adverse events.</population>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 8 weeks</time_frame>
      <desc>All randomized participants who received at least 1 dose of study drug excluding one participant from the placebo group who did not report adverse events and was lost to follow up.</desc>
      <group_list>
        <group group_id="E1">
          <title>50 mg Lasmiditan</title>
          <description>50 mg lasmiditan administered orally (PO)</description>
        </group>
        <group group_id="E2">
          <title>100 mg Lasmiditan</title>
          <description>100 mg lasmiditan administered orally (PO)</description>
        </group>
        <group group_id="E3">
          <title>200 mg Lasmiditan</title>
          <description>200 mg lasmiditan administered orally (PO)</description>
        </group>
        <group group_id="E4">
          <title>400 mg Lasmiditan</title>
          <description>400 mg lasmiditan administered orally (PO)</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Placebo administered orally (PO)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="59" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="82"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="71"/>
                <counts group_id="E4" events="16" subjects_affected="16" subjects_at_risk="70"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Halo vision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Salivary hypersecretion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="82"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="82"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="82"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="71"/>
                <counts group_id="E4" events="16" subjects_affected="16" subjects_at_risk="70"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Feeling of body temperature change</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Feeling of relaxation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Sensation of blood flow</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Limb discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Coordination abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="82"/>
                <counts group_id="E2" events="22" subjects_affected="21" subjects_at_risk="82"/>
                <counts group_id="E3" events="26" subjects_affected="26" subjects_at_risk="71"/>
                <counts group_id="E4" events="27" subjects_affected="26" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Facial paresis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Fine motor delay</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Head discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Hyperkinesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Hypertonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="82"/>
                <counts group_id="E3" events="16" subjects_affected="12" subjects_at_risk="71"/>
                <counts group_id="E4" events="14" subjects_affected="14" subjects_at_risk="70"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Slow response to stimuli</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="82"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="71"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="70"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Taste disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Derealisation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Euphoric mood</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Fear</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Hallucination, visual</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Illusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Peripheral coldness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>One participant from the placebo group did not report adverse events and was lost to follow up.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
      <email>ClinicalTrials.gov@lilly.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

